Receptor News and Research

RSS

Off-label GLP-1 use highlights the cultural pressures driving body anxieties

New obesity drugs that were designed to treat diabetes and obesity are increasingly being used off-label by people without these conditions to achieve slimness and social approval rather than health gains. This perspective maps how such pharmacological thinness interacts with stigma, beauty ideals, digital culture, and inequality, and calls for multinational, intersectional research to understand its full impact.

13 Nov 2025

Scientists reveal how prolonged UV exposure weakens cellular defense against skin cancer

Sunlight is vital for human health as it helps the body produce essential nutrients, such as vitamin D. However, too much sun exposure can significantly increase the risk of skin cancer.

13 Nov 2025

Single-cell study reveals how HPV shapes immune landscape in penile cancer

Although penile cancer represents less than 1% of male malignancies, it carries substantial physical and psychological burden, with a five-year survival rate near 50%.

13 Nov 2025

Innovative research reveals FGD3 as a key player in breast cancer cell death

A naturally occurring protein that tends to be expressed at higher levels in breast cancer cells boosts the effectiveness of some anticancer agents, including doxorubicin, one of the most widely used chemotherapies, and a preclinical drug known as ErSO, researchers report.

13 Nov 2025

Switching APOE4 to APOE2 in adult mice reduces Alzheimer’s pathology and improves memory

Replacing APOE4 with APOE2 in adult mice rapidly reshapes brain lipids and gene expression, even after development is complete. This switch, especially when targeted to astrocytes, reduces amyloid burden, dampens gliosis, and improves associative memory despite E2-like peripheral lipid risks.

12 Nov 2025

Understanding thrombocytopenia in patients with portal hypertension and chronic liver disease

Chronic liver disease (CLD) and its advanced stage, cirrhosis, represent a significant global health burden, with portal hypertension (PH) being a primary driver of disease progression and decompensation.

12 Nov 2025

Discovery of 'Mann-type DLBCL' offers hope for more targeted cancer therapies

Researchers at the University of Southampton have identified a new subtype of lymphoma which could pave the way to improved and more targeted treatments for some blood cancer patients.

11 Nov 2025

The caffeine conundrum in rapid depression treatments

Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic dissection of rapid antidepressant action identifies adenosine as the critical mediator, yet adenosine receptors are the primary target of caffeine, the world's most widely consumed psychoactive substance.

11 Nov 2025

GLP-1 drugs linked to improved survival in colon cancer patients

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists - the class of drugs behind Ozempic, Wegovy and Mounjaro, for example - may do more than regulate blood sugar and weight.

11 Nov 2025

Metformin shows promise in treating AFib recurrence after ablation

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Novel triple receptor agonist shows potent efficacy in lowering high triglycerides

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients with severe hypertriglyceridemia by more than 60%, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Preclinical study reveals dampened neuronal activity in alcohol-exposed mice

A psychedelic found in mushrooms is emerging as a potential treatment for alcohol use disorders. This possibility is due to a compound the body converts the psychedelic into called psilocin, but psilocin's mechanisms remain unclear.

11 Nov 2025

St. Jude study maps treatment strategy for rare infant gliomas

Clinician-scientists at St. Jude Children's Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma (IHG) ever reported, uncovering key factors that could be used to guide treatment strategies for this rare pediatric brain tumor.

11 Nov 2025

Age impacts systemic therapy outcomes in metastatic prostate cancer

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered – chronological age.

10 Nov 2025

Researchers achieve long-term remission with novel T cell therapies for HPV-related cancers

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI) - designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center of the National Institutes of Health, announced findings from two HPV-related studies that highlight the potential of novel T cell therapies to achieve long-lasting remission and complete tumor regression in patients with advanced epithelial cancers.

10 Nov 2025

Single daily polypill improves heart function and quality of life in heart failure patients

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, better quality of life, fewer hospitalizations and greater medication adherence than those taking the medications individually, according to a late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar blood sugar control but significantly greater reductions in body mass index than metformin. These findings highlight the potential of high-potency GLP-1 agents as effective monotherapy options in managing obesity and glycemic control in adolescents.

10 Nov 2025

Blood protein pattern linked to increased risk of hereditary atherosclerosis

A specific pattern of proteins in the blood may reflect an increased risk of hereditary atherosclerosis. This is shown in a new study from Karolinska Institutet, examining close relatives of people who had suffered a heart attack at a young age.

10 Nov 2025

Diabetes drugs semaglutide and tirzepatide show real-world heart benefits

In a large real-world analysis across three U.S. healthcare databases, semaglutide and tirzepatide showed cardiovascular benefits consistent with randomized trials. Semaglutide lowered heart attack and stroke risk versus sitagliptin, while tirzepatide performed comparably to dulaglutide and semaglutide over one year.

10 Nov 2025

Daily oral medication matches injectable therapies in reducing bad cholesterol

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density lipoprotein (LDL or "bad" cholesterol), according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025